RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA

Clinical trials for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA explained in plain language.

Never miss a new study

Get alerted when new RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA trials appear

Sign up with your email to follow new studies for RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental pill aims to hold back recurrent brain tumors

Disease control Ongoing

This study is testing whether a daily pill called vorasidenib can slow down or stop the growth of recurrent low-grade brain tumors (gliomas) in Asian patients who have a specific genetic mutation. Participants will take either the drug or a placebo pill, and researchers will trac…

Matched conditions: RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA

Phase: PHASE3 • Sponsor: Servier • Aim: Disease control

Last updated Apr 02, 2026 05:41 UTC

RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA

Get alerted when new RESIDUAL OR RECURRENT GRADE 2 IDH MUTANT GLIOMA trials appear

Experimental pill aims to hold back recurrent brain tumors